Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis
Fuente:
Wiley Open Access
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Veröffentlicht: |
Wiley
2025
|
| Schlagworte: | |
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1867003590265012226 |
|---|---|
| author | Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran |
| author_facet | Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran |
| collection | Wiley Open Access |
| contents | Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran Hepatology Research AbstractBackground and aimsSjögren's syndrome is a common comorbidity in patients with primary biliary cholangitis (PBC). Anti‐Ro52 autoantibodies against the protein TRIM21 are often seen in Sjögren's syndrome. TRIM21 consists of four domains (PRY/SPRY, Coiled‐Coil, B‐box, and RING domain), each with a specific function. We hypothesized that patients with PBC and concomitant autoantibodies against TRIM21 had a higher risk of developing Sjögren's syndrome.MethodsUsing ELISA, we analyzed plasma from 236 Danish patients with PBC. Binomial regression assessed the risk rates between demographics, serologic variables, PBC‐40 results, and autoantibody positivity.ResultsForty patients (16.9%) tested positive for anti‐Ro52 autoantibodies, with 23 (9.7%) samples positive against Coiled‐Coil, 12 against PRY/SPRY (5.1%), and 10 against RING (4.2%). Increased IgG plasma levels, reports of dry mouth, and a diagnosis of Sjögren's syndrome increased the risk of both anti‐Ro52 and all domain autoantibodies. In the anti‐Ro52 positive subgroup, no less than 14 undiagnosed patients met the criteria for Sjögren's syndrome.ConclusionsWe observed a 16.9% positivity of anti‐Ro52 autoantibodies and an association between having these autoantibodies and elevated IgG, the symptom dry mouth, and having Sjögren's syndrome. Furthermore, we found a sizable undiagnosed group of Sjögren's patients in the anti‐Ro52 positive subgroup. Our results suggest that Sjögren's patients are underdiagnosed in patients with PBC. We propose that patients with PBC be tested for anti‐Ro52 autoantibodies and, if positive, referred for rheumatological examination. 10.1111/hepr.14213 http://creativecommons.org/licenses/by-nc/4.0/ |
| doi_str_mv | 10.1111/hepr.14213 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_hepr_14213 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by-nc/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran Hepatology Research Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis Marie Louise Næstholt Dahl Trine‐Line Korsholm Jakob Hauge Mikkelsen Malene Hvid Ayad Babaee Matias Hauge Böttcher Jesper Bach Hansen Peter Holland‐Fischer Christian Brix Folsted Andersen Henning Grønbæk Bent Deleuran Hepatology Research AbstractBackground and aimsSjögren's syndrome is a common comorbidity in patients with primary biliary cholangitis (PBC). Anti‐Ro52 autoantibodies against the protein TRIM21 are often seen in Sjögren's syndrome. TRIM21 consists of four domains (PRY/SPRY, Coiled‐Coil, B‐box, and RING domain), each with a specific function. We hypothesized that patients with PBC and concomitant autoantibodies against TRIM21 had a higher risk of developing Sjögren's syndrome.MethodsUsing ELISA, we analyzed plasma from 236 Danish patients with PBC. Binomial regression assessed the risk rates between demographics, serologic variables, PBC‐40 results, and autoantibody positivity.ResultsForty patients (16.9%) tested positive for anti‐Ro52 autoantibodies, with 23 (9.7%) samples positive against Coiled‐Coil, 12 against PRY/SPRY (5.1%), and 10 against RING (4.2%). Increased IgG plasma levels, reports of dry mouth, and a diagnosis of Sjögren's syndrome increased the risk of both anti‐Ro52 and all domain autoantibodies. In the anti‐Ro52 positive subgroup, no less than 14 undiagnosed patients met the criteria for Sjögren's syndrome.ConclusionsWe observed a 16.9% positivity of anti‐Ro52 autoantibodies and an association between having these autoantibodies and elevated IgG, the symptom dry mouth, and having Sjögren's syndrome. Furthermore, we found a sizable undiagnosed group of Sjögren's patients in the anti‐Ro52 positive subgroup. Our results suggest that Sjögren's patients are underdiagnosed in patients with PBC. We propose that patients with PBC be tested for anti‐Ro52 autoantibodies and, if positive, referred for rheumatological examination. 10.1111/hepr.14213 http://creativecommons.org/licenses/by-nc/4.0/ |
| title | Anti‐Ro52/TRIM21 autoantibodies predict Sjögren's syndrome in patients with primary biliary cholangitis |
| topic | Hepatology Research |
| url | https://onlinelibrary.wiley.com/doi/10.1111/hepr.14213 |